Effect of Remdesivir on mortality and length of stay in hospitalized COVID-19 patients: A single center study.

Autor: Shaikh Q; Dr. Quratulain Shaikh, FCPS, MSc, Department of Internal Medicine, The Indus Hospital and Health Network, Karachi, Pakistan., Sarfaraz S; Dr. Samreen Sarfaraz, MRCP, Department of Internal Medicine, The Indus Hospital and Health Network, Karachi, Pakistan., Rahim A; Dr. Anum Rahim, MBBS, MSc. Indus Hospital Research Center, The Indus Hospital and Health Network, Karachi, Pakistan., Hussain M; Mujahid Hussain, PharmD, MSc (Clinical Pharmacy), Department of Pharmacy Services, The Indus Hospital and Health Network, Karachi, Pakistan., Shah R; Dr. Rabeea Shah, FCPS, Department of Internal Medicine, The Indus Hospital and Health Network, Karachi, Pakistan., Soomro S; Dr. Sara Soomro, MBBS, Department of Internal Medicine, The Indus Hospital and Health Network, Karachi, Pakistan.
Jazyk: angličtina
Zdroj: Pakistan journal of medical sciences [Pak J Med Sci] 2022 Jan; Vol. 38 (2), pp. 405-410.
DOI: 10.12669/pjms.38.ICON-2022.5779
Abstrakt: Objectives: To see the difference in mortality among hospitalized COVID-19 patients given Remdesivir (RDV) with those who were not given RDV.
Methods: A prospective cohort study was conducted on patients who were admitted to the COVID-19 isolation unit at The Indus Hospital, Korangi Campus Karachi between March and June 2020.
Results: Groups were similar in age and gender distribution. RDV group was more hypoxic, had severe ARDS and needed higher Oxygen support compared to non-RDV group (p=0.000). Median SOFA score was 2 in RDV vs 5 in non-RDV (p=0.000). More than moderate COVID pneumonia was found in 92% of the RDV group while 89% of non-RDV group (p value=0.001). Median day of illness to administer Remdesivir was 10. There was no difference in mortality (45.5% in RDV vs 40.4% in non-RDV; p=0.4) between the two groups. Median length of hospital stay was 12 days (IQR=7.5-14.5) in RDV group compared to 10 days (IQR=6-14) in non-RDV group (p=0.009).
Conclusion: RDV did not show any difference in in-hospital mortality in our patients. More patients had severe ARDS in the RDV group while patients in the non-RDV group had higher SOFA score and multi-organ failure. Length of stay was longer in patients receiving Remdesivir.
(Copyright: © Pakistan Journal of Medical Sciences.)
Databáze: MEDLINE
Externí odkaz: